| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/29/2012 | US8188249 Nucleic acid molecules encoding antibodies to M-CSF |
| 05/29/2012 | US8188228 Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer |
| 05/29/2012 | US8188113 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies |
| 05/29/2012 | US8188112 Naphthalamide derivatives having antiproliferative activity |
| 05/29/2012 | US8188086 Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| 05/29/2012 | US8188084 Pyridinone and pyridazinone derivatives as inhibitors of poly (ADP-ribose) polymerase (PARP) |
| 05/29/2012 | US8188074 Biologically active methylene blue derivatives |
| 05/29/2012 | US8188066 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| 05/29/2012 | US8187600 Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses |
| 05/29/2012 | CA2682849C Sulfonamides and pharmaceutical compositions thereof |
| 05/29/2012 | CA2616914C Egfr-binding antibody |
| 05/29/2012 | CA2516022C Model for studying the role of genes in tumor resistance to chemotherapy |
| 05/29/2012 | CA2512487C Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| 05/29/2012 | CA2496127C Piperidinyl compounds that selectively bind integrins |
| 05/29/2012 | CA2481036C (3z)-(3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors |
| 05/29/2012 | CA2478616C Use of adenoviruses mutated in the va genes for cancer treatment |
| 05/29/2012 | CA2455403C Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses |
| 05/29/2012 | CA2441597C Elongated and multiple spacers in activatible prodrugs |
| 05/29/2012 | CA2417389C Therapeutic polyesters and polyamides |
| 05/29/2012 | CA2395053C Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 05/29/2012 | CA2389429C Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 05/29/2012 | CA2379388C Immunoglobulin fusion proteins |
| 05/29/2012 | CA2368855C Differentiation of monocytes into functional dendritic cells |
| 05/29/2012 | CA2343579C Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| 05/29/2012 | CA2338005C Peptide antagonists of zonulin and methods for use of the same |
| 05/29/2012 | CA2322157C Synthesis of epothilones, intermediates thereto and analogues thereof |
| 05/29/2012 | CA2269118C Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
| 05/29/2012 | CA2268258C Single-chain multiple antigen-binding molecule, its preparation and use |
| 05/29/2012 | CA2220777C Novel heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists |
| 05/24/2012 | WO2012068540A2 Neutralizing anti-ccl20 antibodies |
| 05/24/2012 | WO2012068529A2 Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| 05/24/2012 | WO2012068491A1 Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status |
| 05/24/2012 | WO2012068487A1 Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
| 05/24/2012 | WO2012068483A1 Preselection of subjects for therapeutic treatment based on hypoxic status |
| 05/24/2012 | WO2012068477A1 Methods and compositions for inhibiting angiogenesis and tumor growth |
| 05/24/2012 | WO2012068412A2 Method and compositions for treatment of stat3-responsive cancers and/or renal cancer |
| 05/24/2012 | WO2012068380A2 Methods and compositions for modulating pd1 |
| 05/24/2012 | WO2012068343A1 Quinoline derivatives as pik3 inhibitors |
| 05/24/2012 | WO2012068319A2 Method of treating hematological cancers |
| 05/24/2012 | WO2012068282A1 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer |
| 05/24/2012 | WO2012068231A1 Method of administration and treatment |
| 05/24/2012 | WO2012068211A1 Tricyclic inhibitors of pro-matrix metalloproteinase activation |
| 05/24/2012 | WO2012068209A2 Bisthiazole inhibitors of pro-matrix metalloproteinase activation |
| 05/24/2012 | WO2012068196A1 Bis heteroaryl inhibitors of pro-matrix metalloproteinase activation |
| 05/24/2012 | WO2012068169A2 Substance for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments |
| 05/24/2012 | WO2012068096A2 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| 05/24/2012 | WO2012068073A2 Therapeutic and diagnostic applications targeting tnk-1 |
| 05/24/2012 | WO2012068032A1 Fgfr1 extracellular domain combination therapies |
| 05/24/2012 | WO2012068030A1 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins |
| 05/24/2012 | WO2012067965A1 Nampt and rock inhibitors |
| 05/24/2012 | WO2012067963A1 Nampt inhibitors |
| 05/24/2012 | WO2012067269A1 Aminoalkoxyphenyl compounds and their use in the treatment of disease |
| 05/24/2012 | WO2012067268A1 Cyclic amide compounds and their use in the treatment of disease |
| 05/24/2012 | WO2012067138A1 Novel polymer derivative of cytidine metabolism antagonist |
| 05/24/2012 | WO2012066896A1 Combined pharmaceutical preparation |
| 05/24/2012 | WO2012066581A1 Novel conjugates for targeted drug delivery |
| 05/24/2012 | WO2012066508A1 Pharmaceutical combination of paclitaxel and a cdk inhibitor |
| 05/24/2012 | WO2012066486A1 Compound ethyl 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate, salt, crystalline form, cocrystal, formulation, processes for preparation, application as medicaments, pharmaceutical compositions and new use particularly as inhibitor of aurora kinases |
| 05/24/2012 | WO2012066336A1 Benzylamine compounds as toll -like receptor 7 agonists |
| 05/24/2012 | WO2012066335A1 Phenol compounds als toll -like receptor 7 agonists |
| 05/24/2012 | WO2012066117A1 Polymeric conjugates of active principles, their process of preparation and their polymeric intermediates |
| 05/24/2012 | WO2012066095A1 Crystalline form of an inhibitor of mdm2/4 and p53 interaction |
| 05/24/2012 | WO2012066093A1 Compounds for the modulation of pdz-binding kinase (pbk) expression |
| 05/24/2012 | WO2012066070A1 3-(aminoaryl)-pyridine compounds |
| 05/24/2012 | WO2012066065A1 Phenyl-heteroaryl amine compounds and their uses |
| 05/24/2012 | WO2012066002A1 Flavagline derivatives as neuroprotective agents |
| 05/24/2012 | WO2012065935A1 Methods of treating tumors |
| 05/24/2012 | WO2012065546A1 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| 05/24/2012 | WO2012065384A1 Tromantadine compounds with adamantane structure, derivatives and analogs thereof, and their uses as anti-tumor pharmaceuticals |
| 05/24/2012 | WO2012065383A1 Application of drug memantine with adamantane structure, derivatives and analogues thereof for preventing tumor indication |
| 05/24/2012 | WO2012065362A1 Myomegalin variant 8 and uses thereof |
| 05/24/2012 | WO2012065297A1 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| 05/24/2012 | WO2012018854A3 Pactamycin analogs and methods of use |
| 05/24/2012 | WO2012018761A3 Method of treatment of androgen-mediated cancers |
| 05/24/2012 | WO2012018759A3 Method of treatment of androgen-mediated cancers |
| 05/24/2012 | WO2012018597A9 Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments |
| 05/24/2012 | WO2012016050A3 Chemoradiotherapy for kras-mutant colorectal cancer |
| 05/24/2012 | WO2012011777A3 Kit for diagnosing colorectal cancer and pharmaceutical composition for prevention or treatment of colorectal cancer |
| 05/24/2012 | WO2012009499A3 Assessing thyroid neoplasms and treating cancer |
| 05/24/2012 | WO2012008711A3 Erlotinib dichloroacetate and anti-cancer agent comprising the same |
| 05/24/2012 | WO2011161217A3 Targeting of vegfr2 |
| 05/24/2012 | WO2011130749A3 Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors |
| 05/24/2012 | WO2011051540A8 Androgen receptor modulating compounds |
| 05/24/2012 | WO2011047055A8 Novel mek inhibitors, useful in the treatment of diseases |
| 05/24/2012 | US20120130300 Therapeutic Methods Using Controlled Delivery Devices Having Zero Order Kinetics |
| 05/24/2012 | US20120130147 Methods for the treatment of tumors with indane compounds |
| 05/24/2012 | US20120130146 Continuous administration of cilengitide in cancer treatments |
| 05/24/2012 | US20120130144 Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor |
| 05/24/2012 | US20120130069 Novel indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient |
| 05/24/2012 | US20120129957 Analyzing the fmr1 gene |
| 05/24/2012 | US20120129948 Medical implant producing wear particles with benign body response |
| 05/24/2012 | US20120129947 Amino-alcohol analogues and uses thereof |
| 05/24/2012 | US20120129932 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
| 05/24/2012 | US20120129930 Ketone compounds and compositions for cholesterol management and related uses |
| 05/24/2012 | US20120129927 New Anthraquinone Derivatives |
| 05/24/2012 | US20120129926 Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| 05/24/2012 | US20120129918 Modified oligonucleotides for telomerase inhibition |
| 05/24/2012 | US20120129917 Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
| 05/24/2012 | US20120129916 Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
| 05/24/2012 | US20120129915 Organic compositions to treat hsf1-related diseases |